Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal

Recent studies have confirmed that radioactive iodine therapy after recombinant human TSH (rhTSH) stimulation effectively ablates the normal thyroid remnant. However, no published study has determined the effectiveness of rhTSH preparations on the important endpoint of disease recurrence. Methods: Disease recurrence was retrospectively assessed a median of 2.5 y after radioiodine remnant ablation (RRA) in 394 consecutive thyroid cancer patients (93% papillary, 71% female, 47 ± 15 y old [mean ± SD], median 131I dose of 3,996 MBq [108 mCi]). Results: Similar rates of clinically evident disease recurrence (4% rhTSH vs. 7% thyroid hormone withdrawal [THW], P = not statistically significant) and residual thyroid bed uptake without other evidence of persistent disease (4% rhTSH vs. 7% THW, P = not statistically significant) were seen in the 320 patients undergoing rhTSH-assisted RRA and the 74 patients prepared for RRA by THW. When the definition of no clinical evidence of disease included a suppressed thyroglobulin level of less than 1 ng/mL and a stimulated thyroglobulin level of less than 2 ng/mL, rhTSH-assisted RRA was associated with significantly higher rates of no clinical evidence of disease (74% rhTSH vs. 55% THW, P = 0.02) and significantly lower rates of persistent disease (19% rhTSH vs. 32% THW, P = 0.02) than was RRA after THW. Patients selected for rhTSH-assisted RRA were older (48 ± 15 vs. 44 ± 15 y, P = 0.03) and received a slightly higher administered activity of 131I (median, 4,033 MBq [109 mCi] vs. 3,811 MBq [103 mCi], P = 0.01) but did not differ with respect to sex, histology, disease stage, or mean time to recurrence (19 ± 9 mo for rhTSH vs. 20 ± 16 mo for THW). Conclusion: rhTSH-assisted RRA is associated with rates of clinically evident disease recurrence and persistent uptake in the thyroid bed that are similar to those for traditional THW.

[1]  A. Pinchera,et al.  Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. , 2002, The Journal of clinical endocrinology and metabolism.

[2]  B. Weintraub,et al.  A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. , 2006, The Journal of clinical endocrinology and metabolism.

[3]  M. Luster,et al.  rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. , 2005, Endocrine-related cancer.

[4]  S. Larson,et al.  A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  R. Robbins,et al.  Recombinant Human Thyrotropin and Thyroid Cancer Management , 2003 .

[6]  H. Gerstein,et al.  A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer , 2004 .

[7]  P. Dasgupta,et al.  Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. , 2006, European urology.

[8]  R. Robbins,et al.  Clinical review 156: Recombinant human thyrotropin and thyroid cancer management. , 2003, The Journal of clinical endocrinology and metabolism.

[9]  B. Weintraub,et al.  A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. , 1999, The Journal of clinical endocrinology and metabolism.

[10]  R. Wahl,et al.  Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. , 2006, The Journal of clinical endocrinology and metabolism.

[11]  M. Luster,et al.  Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. , 2005, Thyroid : official journal of the American Thyroid Association.

[12]  M. Schlumberger [Papillary and follicular thyroid carcinoma]. , 2000, Annales d'endocrinologie.

[13]  Gerard M Doherty,et al.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[14]  S. Larson,et al.  Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? , 2002, The Journal of clinical endocrinology and metabolism.

[15]  Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.

[16]  Stephanie L. Lee,et al.  A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[17]  G. Johnston,et al.  Radioiodine therapy for thyroid cancer. , 1995, Endocrinology and metabolism clinics of North America.

[18]  J. Luton,et al.  [Thyroid tumors]. , 1998, Archives d'anatomie et de cytologie pathologiques.

[19]  A. Pinchera,et al.  Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. , 2001, The Journal of clinical endocrinology and metabolism.

[20]  B. Ferrell,et al.  Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. , 1997, Thyroid : official journal of the American Thyroid Association.

[21]  L. Duntas,et al.  Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. , 2004, European journal of endocrinology.

[22]  H. Gerstein,et al.  Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. , 2004, The Journal of clinical endocrinology and metabolism.

[23]  S. Larson,et al.  Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. , 2004, The Journal of clinical endocrinology and metabolism.

[24]  G. Mariani,et al.  Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. , 2003, The Journal of clinical endocrinology and metabolism.

[25]  J. Garber,et al.  Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. , 1997, The New England journal of medicine.